Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: Indian J Med Res)
Source: Indian J Med Res - September 14, 2023 Category: Research Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: The Indian Journal of Medical Research)
Source: The Indian Journal of Medical Research - September 14, 2023 Category: Biomedical Science Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: Indian J Med Res)
Source: Indian J Med Res - September 14, 2023 Category: Research Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: The Indian Journal of Medical Research)
Source: The Indian Journal of Medical Research - September 14, 2023 Category: Biomedical Science Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: Indian J Med Res)
Source: Indian J Med Res - September 14, 2023 Category: Research Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: The Indian Journal of Medical Research)
Source: The Indian Journal of Medical Research - September 14, 2023 Category: Biomedical Science Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: Indian J Med Res)
Source: Indian J Med Res - September 14, 2023 Category: Research Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: The Indian Journal of Medical Research)
Source: The Indian Journal of Medical Research - September 14, 2023 Category: Biomedical Science Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: Indian J Med Res)
Source: Indian J Med Res - September 14, 2023 Category: Research Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: The Indian Journal of Medical Research)
Source: The Indian Journal of Medical Research - September 14, 2023 Category: Biomedical Science Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: Indian J Med Res)
Source: Indian J Med Res - September 14, 2023 Category: Research Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: The Indian Journal of Medical Research)
Source: The Indian Journal of Medical Research - September 14, 2023 Category: Biomedical Science Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: Indian J Med Res)
Source: Indian J Med Res - September 14, 2023 Category: Research Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: The Indian Journal of Medical Research)
Source: The Indian Journal of Medical Research - September 14, 2023 Category: Biomedical Science Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research

Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22 (Source: Indian J Med Res)
Source: Indian J Med Res - September 14, 2023 Category: Research Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research